Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results to May 31, 2024

Rhea-AI Summary

Mesa Laboratories (NASDAQ:MLAB) has revised the earnings announcement date for its unaudited fourth quarter and full fiscal year 2024 results to May 31, 2024. The press release, disclosing financial outcomes for the period ending March 31, 2024, will be issued at approximately 8:00 A.M. Eastern time on that day.

Mesa's Form 10-K, detailing these results, will also be filed on May 31. The delay is attributed to finalizing calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill in the Clinical Genomics and Biopharmaceutical Development divisions. The deadline for this filing with the SEC is June 14, 2024.

Mesa Laboratories specializes in life sciences tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, ensuring product integrity and improving quality of life globally.

Positive

• Earnings announcement rescheduled to May 31, 2024, providing a clear timeline for investors.
• Timely filing of Form 10-K on May 31, aligning with SEC deadlines.
• Company specializes in life sciences tools and quality control solutions, indicating a focus on high-demand sectors.
• Involvement in pharmaceutical, healthcare, and medical device industries, which are typically stable sectors.

Negative

• Delay in earnings announcement due to finalizing calculations and technical accounting for impairments.
• Impairments of long-lived assets and goodwill in Clinical Genomics and Biopharmaceutical Development divisions may indicate underlying business challenges.
• Potential negative impact on investor sentiment due to the delay in financial results disclosure.

LAKEWOOD, Colo., May 22, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024. Mesa’s Form 10-K will be filed the same day. The earnings announcement has been delayed as we finalize the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions.

Mesa’s Form 10-K filing deadline with the SEC is June 14, 2024.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

For more information about the Company, please visit our website at www.mesalabs.com.

FAQ

When is Mesa Laboratories (MLAB) announcing its fourth quarter and full fiscal year 2024 results?

Mesa Laboratories will announce its fourth quarter and full fiscal year 2024 results on May 31, 2024.

Why has Mesa Laboratories (MLAB) delayed its earnings announcement for Q4 and fiscal year 2024?

The delay is due to finalizing calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill.

What divisions of Mesa Laboratories (MLAB) are affected by the impairments?

The Clinical Genomics and Biopharmaceutical Development divisions are affected by the impairments.

When will Mesa Laboratories (MLAB) file its Form 10-K for the fiscal year ending March 31, 2024?

Mesa Laboratories will file its Form 10-K on May 31, 2024.

What is the SEC filing deadline for Mesa Laboratories' (MLAB) Form 10-K?

The SEC filing deadline for Mesa Laboratories' Form 10-K is June 14, 2024.